Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
     Dosage & Administration
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

Dosage and Administration

  • Ventavis® (iloprost) Inhalation Solution should be taken 6 to 9 times per day (no more than once every 2 hours).1
  • Dosing recommended during waking hours (90% of clinical trial patients never inhaled Ventavis during sleeping hours).1
  • Ventavis is intended for inhalation administration via a breath-actuated pulmonary drug delivery system: the I-neb AAD System.
  • The first inhaled dose should be 2.5 mcg (as delivered at the mouthpiece).1
    • If the 2.5-mcg dose is well tolerated, dosing should be increased to 5.0 mcg and maintained.
    • If the 5.0-mcg dose is not tolerated, dosing should be reduced to and maintained at 2.5 mcg.
    • For patients maintained at 5 mcg who have repeatedly experienced extended treatment times, transition to 20 mcg/mL.
  • For each inhalation treatment, follow what is described in the Full Prescribing Information.
    • After each inhalation session, any solution remaining in the I-neb AAD System medication chamber should be discarded.
    • Use of remaining solution will result in unpredictable dosing.

†The 20 mcg/mL concentration is intended for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. Ventavis 10 mcg/mL ampules are still available. Ventavis should be taken 6 to 9 times daily, at least 2 hours apart.1

‡Data based on an in vitro study with a manually generated 28.3-L/min, 15-sec inhalation cycle breathing pattern.

The I-neb AAD System is a registered trademark of Philips Respironics.

1. Ventavis (iloprost) Full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2009.



* In the AIR pivotal trial, Ventavis delivered significant patient improvement in a composite endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

IMPORTANT SAFETY INFORMATION:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).

Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
©2010 Actelion Pharmaceuticals US, Inc. All rights reserved.

ACTELION